Crossmark Global Holdings Inc. Increases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Crossmark Global Holdings Inc. lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 16.1% in the third quarter, Holdings Channel reports. The fund owned 7,161 shares of the biotechnology company’s stock after purchasing an additional 994 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Sarepta Therapeutics were worth $894,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Innealta Capital LLC bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at approximately $31,000. New Covenant Trust Company N.A. purchased a new stake in Sarepta Therapeutics during the 1st quarter valued at $32,000. Nkcfo LLC bought a new stake in Sarepta Therapeutics in the second quarter worth $43,000. Riggs Asset Managment Co. Inc. boosted its stake in Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after buying an additional 75 shares during the period. Finally, UMB Bank n.a. increased its position in Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 197 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Stock Down 3.0 %

Sarepta Therapeutics stock opened at $109.11 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm has a market cap of $10.42 billion, a P/E ratio of 87.29 and a beta of 0.81. The business has a fifty day moving average of $124.21 and a two-hundred day moving average of $132.49. Sarepta Therapeutics, Inc. has a twelve month low of $78.67 and a twelve month high of $173.25.

Analysts Set New Price Targets

Several research firms have recently issued reports on SRPT. Piper Sandler lowered their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Evercore ISI dropped their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Royal Bank of Canada reissued an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Finally, Guggenheim upped their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $181.33.

Insider Buying and Selling

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 7.70% of the stock is currently owned by company insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.